hero Hcp

HELP YOUR PATIENTS RELIEVE THE BURDEN OF EXCESS VISCERAL ABDOMINAL FAT

Help Curb Excess Visceral Abdominal Fat

EGRIFTA SV®: The only once-daily subcutaneous injection with a small volume of administration.
  • Concentrated strength, dosed in a single vial
  • Injection volume of only 0.35 mL
  • Small needle size (½” 30-gauge needle)
  • Store at room temperature (no refrigeration required)
The only FDA approved treatment* indicated for the treatment of excess visceral abdominal fat in HIV-infected adult patients with lipodystrophy

Proven to significantly reduce excess abdominal fat.

EGRIFTA SV® is not indicated for weight loss management.

See the Results
How does EGRIFTA SV® work?

It stimulates the body's own pulsatile release of growth hormone.

Learn about the mechanism of action
Get your patients started and staying on therapy

THERA patient support® offers comprehensive services and personal support for you and your patients.

Find out more

*An approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.